SCHEMBL155980

SCHEMBL155980

CCCCCCCCC=CCCCCCCCNC(=O)Cc1ccc(O)c(O)c1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 3/20 0.85
▸ GPR119 Q8TDV5 1/20 0.73
▸ MAPT P10636 3/20 0.71
▸ HPGD P15428 2/20 0.71
▸ HSD17B10 Q99714 2/20 0.71
▸ KDM4E B2RXH2 1/20 0.71
▸ NPC1 O15118 1/20 0.71
▸ GMNN O75496 1/20 0.71
▸ USP2 O75604 1/20 0.71
▸ LMNA P02545 1/20 0.71
▸ TP53 P04637 1/20 0.71
▸ CYP1A2 P05177 1/20 0.71
▸ POLB P06746 1/20 0.71
▸ CYP3A4 P08684 1/20 0.71
▸ CYP2C9 P11712 1/20 0.71
▸ IDE P14735 1/20 0.71
▸ ALOX15 P16050 1/20 0.71
▸ NFKB1 P19838 1/20 0.71
▸ MAPK1 P28482 1/20 0.71
▸ CYP2C19 P33261 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL155979 1.00 TRPV1 (0.85) TRPV1GPR119MAPTHPGDHSD17B10
SCHEMBL159764 1.00 TRPV1 (0.85) TRPV1GPR119MAPTHPGDHSD17B10
SCHEMBL10548485 0.92 TRPV1 (1.00) TRPV1GPR119MAPTHPGDHSD17B10
SCHEMBL29530774 0.92 TRPV1 (1.00) TRPV1GPR119MAPTHPGDHSD17B10
SCHEMBL28942175 0.92 TRPV1 (1.00) TRPV1GPR119MAPTHPGDHSD17B10
SCHEMBL504255 0.87 TRPV1 (0.70) TRPV1MAPTHPGDTP53CYP1A2
SCHEMBL504257 0.87 TRPV1 (0.70) TRPV1MAPTHPGDTP53CYP1A2
SCHEMBL9808674 0.87 TRPV1 (0.70) TRPV1MAPTHPGDTP53CYP1A2
SCHEMBL29380151 0.87 TRPV1 (0.70) TRPV1MAPTHPGDTP53CYP1A2
SCHEMBL10946428 0.86 TRPV1 (0.61) TRPV1GPR119MAPTHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426644-B2 Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase MITOTEK, LLC (US) 2013-04-23 — — US claimed
US-20120059064-A1 Compositions and Methods For Inhibiting an Isoform of Human Manganese Superoxide Dismutase MITOTEK, LLC (US) 2012-03-08 — — US claimed
US-7989499-B2 Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase MITOTEK, LLC (US) 2011-08-02 — — US claimed
US-20080287548-A1 Compositions and Methods For Inhibiting an Isoform of Human Manganese Superoxide Dismutase MITOTEK, LLC 2008-11-20 — — US claimed
EP-1850667-A2 COMPOSITIONS AND METHODS FOR INHIBITING AN ISOFORM OF HUMAN MANGANESE SUPEROXIDE DISMUTASE Anziano, Paul Q. (US) 2007-11-07 — — EP claimed
WO-2006086422-A2 COMPOSITIONS AND METHODS FOR INHIBITING AN ISOFORM OF HUMAN MANGANESE SUPEROXIDE DISMUTASE ANZIANO PAUL Q (US) 2006-08-17 — — WO claimed
US-20130289123-A1 Compositions and Methods for Inhibiting an Isoform of Human Manganese Superoxide Dismutase MITOTEK, LLC (US) 2013-10-31 — — US disclosed
US-8426644-B2 Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase MITOTEK, LLC (US) 2013-04-23 — — US disclosed
US-20120059064-A1 Compositions and Methods For Inhibiting an Isoform of Human Manganese Superoxide Dismutase MITOTEK, LLC (US) 2012-03-08 — — US disclosed
US-7989499-B2 Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase MITOTEK, LLC (US) 2011-08-02 — — US disclosed
US-20080287548-A1 Compositions and Methods For Inhibiting an Isoform of Human Manganese Superoxide Dismutase MITOTEK, LLC 2008-11-20 — — US disclosed
EP-1850667-A2 COMPOSITIONS AND METHODS FOR INHIBITING AN ISOFORM OF HUMAN MANGANESE SUPEROXIDE DISMUTASE Anziano, Paul Q. (US) 2007-11-07 — — EP disclosed
WO-2006086422-A2 COMPOSITIONS AND METHODS FOR INHIBITING AN ISOFORM OF HUMAN MANGANESE SUPEROXIDE DISMUTASE ANZIANO PAUL Q (US) 2006-08-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130289123-A1 Compositions and Methods for Inhibiting an Isoform of Human Manganese Superoxide Dismutase SOD1, SOD3, PRDX3 TRPV1 4807/4885GPR119 4044/4885MAPT 2191/4885
US-20120059064-A1 Compositions and Methods For Inhibiting an Isoform of Human Manganese Superoxide Dismutase SOD1, SOD3, PRDX3 TRPV1 4807/4885GPR119 4044/4885MAPT 2191/4885
US-20080287548-A1 Compositions and Methods For Inhibiting an Isoform of Human Manganese Superoxide Dismutase SOD1, SOD3, PRDX3 TRPV1 4807/4885GPR119 4044/4885MAPT 2191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback